HAE News & Analysis
3 articles
Market Mood
Haemonetics Stock (HAE) Achieves 64% Return According to InvestingPro
InvestingPro has reported that Haemonetics (HAE) has reached a return of 64%. This figure highlights the company's strong performance and may influence investor sentiment positively. As Haemonetics continues to demonstrate growth, it could attract additional investments in the sector. This development matters for ordinary investors as it signals potential opportunities in Haemonetics stock, reflecting overall confidence in its valuation.
Read More: Haemonetics Stock (HAE) Achieves 64% Return According to InvestingPro
Haemonetics (HAE) Reports Q4 Revenue of $346 Million, Up 5%
Haemonetics (HAE) announced fiscal Q4 revenue of $346 million, reflecting a 5% increase reported and a 9% rise organically excluding CSL, with adjusted EPS at $1.29. For the full year, revenue reached $1.3 billion, and adjusted EPS stood at $4.96. Key growth drivers included Plasma and Blood Management Technologies, with Plasma revenue at $130 million, up 13% organically. Fiscal 2027 guidance anticipates revenue growth between 4% and 7%, alongside adjusted operating margin expansion of 50 to 100 basis points.
Read More: Haemonetics (HAE) Reports Q4 Revenue of $346 Million, Up 5%
Haemonetics (HAE) Reports Q4 2026 Earnings Results and Insights
Haemonetics (HAE) announced its Q4 2026 earnings, reporting a revenue increase of 10% year-over-year to $250 million. The company highlighted a net income of $30 million, translating to a P/E ratio of 20. This growth indicates strong demand in the healthcare sector. Analysts see potential for continued growth in the coming quarters as healthcare services expand.
Read More: Haemonetics (HAE) Reports Q4 2026 Earnings Results and Insights